Antibe Therapeutics (ATBPF) Stock Price, News & Analysis

Company Overview

Antibe Therapeutics Inc. is a Canadian biotechnology company focused on developing gastrointestinal-sparing anti-inflammatory and analgesic medicines. The company’s research has centered on hydrogen sulfide–releasing nonsteroidal anti-inflammatory drugs (NSAIDs), an approach intended to preserve the pain-relieving and anti-inflammatory benefits of conventional NSAIDs while reducing the risk of gastrointestinal injury and other treatment-related complications.

Antibe’s lead drug candidate was ATB-346, a hydrogen sulfide–releasing derivative of naproxen developed for the treatment of acute and chronic pain. The company also worked on additional compounds, including ATB-352, as part of a broader pipeline targeting pain and inflammation. Its development programs were primarily directed toward pharmaceutical and clinical markets in North America and other international jurisdictions.

Antibe was based in Toronto, Ontario, and its shares traded in Canada before also being quoted over the counter in the United States under the symbol ATBPF. The company encountered significant financial and operational challenges during the early 2020s, and public disclosures indicated that it suspended or wound down operations while pursuing creditor-protection and restructuring alternatives. Because its corporate status and leadership have changed over time, current management information may not be reliably available.

Key Stats

• Today's Range: $0.22 to $0.22
• 50-Day Range: $0.22 to $0.22
• 52-Week Range: $0.11 to $0.89
• Volume: N/A
• Average Volume: 27,352 shs
• Market Capitalization: $11.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/13/2023
• Today: 10/14/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ATBPF
• CIK: N/A
• Web: www.antibethera.com
• Phone: (416) 922-3460
• Fax: N/A
• Employees: 11
• Year Founded: 2009

Profitability

• EPS (Trailing Twelve Months): ($0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.73 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -56.48%
• Return on Assets: -29.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.06
• Quick Ratio: 10.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.58 per share
• Price / Book: 0.37

Miscellaneous

• Outstanding Shares: 52,981,000
• Free Float: 48,238,000
• Market Cap: $11.42 million
• Optionable: Not Optionable
• Beta: 0.51